Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT
Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT
复制标题
DOI：
10.1038/bmt.2010.48
复制
发表时间：
2010-12-01
影响因子：
4.8
通讯作者：
Kurokawa, M.
中科院分区：
文献类型：
--
作者：
Ueda, K.;Watadani, T.;Kurokawa, M.
晚发性非感染性肺部并发症(LONIPC)对异基因造血干细胞移植(allo-HSCT)患者的生命构成威胁。然而，LONIPC对生存的影响还没有得到适当的评估，对治疗效果也知之甚少。我们对我们研究所的290例allo-HSCT受者进行了回顾性调查，并回顾了44例被诊断为LONIPC的患者的临床表现。LONIPC与慢性移植物抗宿主病的发生率显著相关(P
Late-onset noninfectious pulmonary complications (LONIPCs) are life threatening for allogeneic hematopoietic SCT (allo-HSCT) recipients. However, the impact of LONIPCs on survival has not been properly evaluated and little is known about treatment efficacy. We retrospectively investigated 290 allo-HSCT recipients in our institute and reviewed the clinical aspects of 44 patients who had been diagnosed with LONIPCs. LONIPCs were significantly associated with higher rates of chronic GVHD (P